TG Therapeutics Inc.(TGTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

TGTX TG Therapeutics Inc.

盘前交易 09-29 08:28:22 EDT

56.19

-1.24

-2.16%

盘前56.01

-0.18-0.32%

07:31 EDT

最高57.66	最低55.88	成交量144.24万
今开57.35	昨收57.43	日振幅3.10%
总市值86.02亿	流通市值79.53亿	总股本1.53亿
成交额8,157万	换手率1.02%	流通股本1.42亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"TGTX","market":"US","secType":"STK","nameCN":"TG Therapeutics Inc.","latestPrice":56.19,"timestamp":1790625600000,"preClose":57.43,"halted":0,"volume":1442422,"hourTrading":{"tag":"盘前","latestPrice":56.01,"preClose":56.19,"latestTime":"07:31 EDT","volume":676,"amount":38180.038572,"timestamp":1790681465842,"change":-0.18,"changeRate":-0.003203,"amplitude":0.028653},"delay":0,"changeRate":-0.02159150269893787,"floatShares":141537422,"shares":153093879,"eps":2.768865,"marketStatus":"盘前交易","change":-1.24,"latestTime":"09-29 08:28:22 EDT","open":57.35,"high":57.66,"low":55.88,"amount":81574102.007164,"amplitude":0.030994,"askPrice":56.54,"askSize":21,"bidPrice":56.01,"bidSize":21,"shortable":3,"etf":0,"ttmEps":2.768865,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790688600000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1128657600000,"exchange":"NASDAQ","adjPreClose":56.19,"preHourTrading":{"tag":"盘前","latestPrice":56.01,"preClose":56.19,"latestTime":"07:31 EDT","volume":676,"amount":38180.038572,"timestamp":1790681465842,"change":-0.18,"changeRate":-0.003203,"amplitude":0.028653},"postHourTrading":{"tag":"盘后","latestPrice":56.0705,"preClose":56.19,"latestTime":"19:30 EDT","volume":129562,"amount":7282183.0299,"timestamp":1790638205580,"change":-0.1195,"changeRate":-0.002127,"amplitude":0.002127},"volumeRatio":0.8200093324564118,"impliedVol":0.6253,"impliedVolPercentile":0.62},"requestUrl":"/m/hq/s/TGTX","defaultTab":"news","newsList":[{"id":"1197695879","title":"异动解读｜TG Therapeutics盘中上涨5.4%，报55.9美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1197695879","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197695879?lang=zh_cn&edition=full","pubTime":"2026-09-17 00:31","pubTimestamp":1789576279,"startTime":"0","endTime":"0","summary":"9月17日，TG Therapeutics盘中上涨5.4%，报55.9美元/股，成交额6306.79万美元。TG Therapeutics所在的生物科技行业中，个股表现分化，其中Moderna涨2.16%，吉利德科学涨1.7%，安进涨0.57%，艾伯维涨0.26%，Revolution Medicines跌2.92%。TG Therapeutics是一家商业化阶段的生物制药公司，专注于B细胞介导疾病新疗法的开发和商业化，其核心产品BRIUMVI已获美国、欧盟和英国批准用于治疗复发性多发性硬化症成人患者。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165497219","title":"异动解读｜TG Therapeutics盘中上涨9.39%，报55.31美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1165497219","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165497219?lang=zh_cn&edition=full","pubTime":"2026-08-22 00:13","pubTimestamp":1787328822,"startTime":"0","endTime":"0","summary":"8月21日，TG Therapeutics盘中上涨9.39%，报55.31美元/股，成交额1.49亿美元。TG Therapeutics所在的生物科技行业中，个股表现活跃，其中Moderna涨10.8%，艾伯维涨1.46%，安进涨1.78%，再生元制药涨1.89%，吉利德科学涨2.69%。TG Therapeutics是一家商业化阶段的生物制药公司，专注于B细胞介导疾病新疗法的开发和商业化，其核心产品BRIUMVI已获美国、欧盟和英国批准用于治疗复发性多发性硬化症成人患者。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100007747","title":"异动解读｜TG Therapeutics盘中上涨5.01%，Q2营收超预期且上调全年收入指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1100007747","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100007747?lang=zh_cn&edition=full","pubTime":"2026-08-05 03:35","pubTimestamp":1785872158,"startTime":"0","endTime":"0","summary":"8月5日，TG Therapeutics盘中上涨5.01%，报48.49美元/股，成交额9052.41万美元。消息面上，公司Q2总营收约2.40亿美元，超出市场预期的2.30亿美元，同时上调全年BRIUMVI收入指引。此前因Q2每股收益仅0.05美元、大幅低于一致预期的0.33美元，股价一度下跌约7%，当前反弹或反映市场对营收端超预期及收入指引上调的重新定价。TG Therapeutics是一家商业化阶段的生物制药公司，专注于B细胞介导疾病新疗法的开发，核心产品BRIUMVI已获美国、欧盟及英国批准用于治疗复发性多发性硬化症。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117147741","title":"异动解读｜TG Therapeutics盘中下跌5.35%，Q2每股收益大幅不及预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1117147741","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117147741?lang=zh_cn&edition=full","pubTime":"2026-08-03 21:53","pubTimestamp":1785765215,"startTime":"0","endTime":"0","summary":"8月3日，TG Therapeutics盘中下跌5.35%，报47.41美元/股，成交额4289.35万美元。然而，连续第三个季度每股收益大幅不及预期，令市场对其费用控制及盈利转化能力的担忧显著加剧，营收利好未能对冲盈利端的持续疲软。TG Therapeutics是一家商业化阶段的生物制药公司，专注于B细胞介导疾病新疗法的开发，其核心产品BRIUMVI已获美国、欧盟及英国批准用于治疗复发性多发性硬化症。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"TG Therapeutics盘中下跌5.35%，Q2每股收益大幅不及预期","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178355484","title":"异动解读 | TG Therapeutics盘中大跌7%，Q2每股收益大幅不及预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1178355484","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178355484?lang=zh_cn&edition=full","pubTime":"2026-08-03 21:46","pubTimestamp":1785764781,"startTime":"0","endTime":"0","summary":"TG Therapeutics Inc.今日盘中大跌7.00%，引发市场广泛关注。尽管营收方面录得2.40亿美元，超出市场预期的2.30亿美元，但盈利端的严重不及预期令投资者信心受挫。值得注意的是，这已是公司连续第三个季度每股收益大幅不及预期，市场对其盈利能力的担忧进一步加剧。TG Therapeutics是一家商业化阶段的生物制药公司，专注于B细胞介导疾病新疗法的开发，其核心产品BRIUMVI已获美国、欧盟及英国批准用于治疗复发性多发性硬化症。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["TGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166576818","title":"异动解读 | TG Therapeutics盘前大跌5.37%，Q2每股收益大幅不及预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1166576818","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166576818?lang=zh_cn&edition=full","pubTime":"2026-08-03 19:26","pubTimestamp":1785756374,"startTime":"0","endTime":"0","summary":"TG Therapeutics Inc.今日盘前股价大跌5.37%，引发市场广泛关注。尽管营收方面录得2.40亿美元，超出市场预期的2.30亿美元，但盈利端的严重不及预期令投资者信心受挫。值得注意的是，这已是公司连续第三个季度每股收益大幅不及预期，市场对其盈利能力的担忧进一步加剧。TG Therapeutics是一家商业化阶段的生物制药公司，专注于B细胞介导疾病新疗法的开发，其核心产品BRIUMVI已获美国、欧盟及英国批准用于治疗复发性多发性硬化症。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["TGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195618406","title":"异动解读｜TG Therapeutics盘前下跌5.37%，Q2每股收益大幅不及预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1195618406","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195618406?lang=zh_cn&edition=full","pubTime":"2026-08-03 19:25","pubTimestamp":1785756304,"startTime":"0","endTime":"0","summary":"8月3日，TG Therapeutics盘前下跌5.37%，报49.24美元/股，成交额76.17万美元。值得注意的是，这已是公司连续第三个季度每股收益大幅不及预期，市场对其盈利能力的担忧加剧。TG Therapeutics是一家商业化阶段的生物制药公司，专注于B细胞介导疾病新疗法的开发，其核心产品BRIUMVI已获美国、欧盟及英国批准用于治疗复发性多发性硬化症。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"TG Therapeutics盘前下跌5.37%，Q2每股收益大幅不及预期","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105581787","title":"TG Therapeutics启动Briumvi治疗难治性精神分裂症二期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1105581787","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105581787?lang=zh_cn&edition=full","pubTime":"2026-07-06 19:32","pubTimestamp":1783337524,"startTime":"0","endTime":"0","summary":"TG Therapeutics公司宣布，已正式启动一项针对其药物Briumvi用于治疗难治性精神分裂症患者的二期临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TGTX","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193128094","title":"异动解读｜TG Therapeutics盘中上涨6.88%，报56.51美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1193128094","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193128094?lang=zh_cn&edition=full","pubTime":"2026-06-22 21:50","pubTimestamp":1782136231,"startTime":"0","endTime":"0","summary":"6月22日，TG Therapeutics盘中上涨6.88%，报56.51美元/股，成交额1762.9万美元。TG Therapeutics所在的生物科技行业中，个股中，Apogee Therapeutics涨46.82%，艾伯维公司涨4.75%，吉利德科学涨0.01%，再生元制药公司跌0.94%，Moderna跌3.31%。TG Therapeutics是一家商业化阶段的生物制药公司，专注于B细胞介导疾病新疗法的收购、开发和商业化，其产品BRIUMVI已获美国、欧盟和英国批准用于治疗复发性多发性硬化症成人患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115330337","title":"TG Therapeutics 启动 Briumvi 作为重症肌无力患者 Efgartigimod 诱导后维持治疗的二期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1115330337","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115330337?lang=zh_cn&edition=full","pubTime":"2026-06-09 19:33","pubTimestamp":1781004808,"startTime":"0","endTime":"0","summary":"TG Therapeutics 公司宣布，已启动一项二期临床试验，旨在评估其药物 Briumvi（通用名：ublituximab）作为维持疗法，用于治疗那些在完成 Efgartigimod 诱导期后的重症肌无力（Mg）患者。\n这项研究将探索 Briumvi 在维持疾病缓解方面的潜力，为重症肌无力患者提供一种新的、可能更便捷的长期治疗方案。试验设计将重点关注药物的安全性、耐受性以及维持临床疗效的能力。此举标志着 TG Therapeutics 在拓展其核心产品 Briumvi 适应症方面迈出了重要一步，特别是在自身免疫性疾病治疗领域。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","TGTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100402307","title":"TG Therapeutics 皮下注射Briumvi耐受性良好，安全性特征与静脉剂型一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1100402307","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100402307?lang=zh_cn&edition=full","pubTime":"2026-06-09 19:31","pubTimestamp":1781004697,"startTime":"0","endTime":"0","summary":"TG Therapeutics 公司宣布，其皮下注射剂型的Briumvi（ublituximab）在一项研究中普遍耐受性良好，其安全性特征与此前已获批准的静脉注射剂型保持一致。\n这一积极数据进一步支持了Briumvi作为多发性硬化症治疗方案的潜力，并为患者提供了更便捷的给药选择。皮下注射方式有望缩短治疗时间，改善患者的治疗体验。公司将继续推进相关临床开发计划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TGTX","BK4139","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136500698","title":"TG Therapeutics公布皮下注射Briumvi治疗重症肌无力的1期试验积极顶线数据，并启动潜在注册导向的随机2期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1136500698","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136500698?lang=zh_cn&edition=full","pubTime":"2026-06-09 19:31","pubTimestamp":1781004677,"startTime":"0","endTime":"0","summary":"TG Therapeutics公司宣布，其皮下注射制剂Briumvi在治疗重症肌无力患者的1期临床试验中获得了积极的顶线数据。基于这些积极结果，公司已启动一项潜在的注册导向性随机2期试验，旨在进一步评估该疗法的有效性与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TGTX","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119349695","title":"TG Therapeutics公布皮下注射Briumvi®（Ublituximab-Xiiy）一期试验积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1119349695","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119349695?lang=zh_cn&edition=full","pubTime":"2026-06-03 19:30","pubTimestamp":1780486232,"startTime":"0","endTime":"0","summary":"TG Therapeutics公司宣布，其皮下注射剂型Briumvi®（Ublituximab-Xiiy）的一期临床试验取得了积极成果。该试验旨在评估这种新给药方式的安全性、耐受性及药代动力学特征。初步数据显示，皮下注射方案展现出良好的耐受性，其药代动力学特征与已获批的静脉输注剂型一致，这为患者提供了一种潜在更便捷的治疗选择。Briumvi®是一种靶向CD20的单克隆抗体，目前已获批用于治疗复发型多发性硬化症。此次皮下制剂的积极进展，有望进一步拓展该药物的应用便利性，并可能增强其在市场竞争中的优势。公司表示，将基于这些数据与监管机构进行沟通，以确定后续的开发路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TGTX","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149993994","title":"TG Therapeutics公布ULTIMATE III期试验在初治复发型多发性硬化症患者中的事后分析数据，发表于《免疫学前沿》","url":"https://stock-news.laohu8.com/highlight/detail?id=1149993994","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149993994?lang=zh_cn&edition=full","pubTime":"2026-06-01 19:31","pubTimestamp":1780313497,"startTime":"0","endTime":"0","summary":"TG Therapeutics公司宣布，其针对初治复发型多发性硬化症（RMS）患者开展的ULTIMATE I和II期3期试验的事后分析数据，已在《免疫学前沿》期刊上发表。该数据的发布为评估相关疗法在特定患者群体中的表现提供了进一步的深入见解。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TGTX","BK4139","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191996105","title":"TG Therapeutics次要终点与既往研究一致；未观察到新的安全性信号","url":"https://stock-news.laohu8.com/highlight/detail?id=1191996105","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191996105?lang=zh_cn&edition=full","pubTime":"2026-05-27 19:34","pubTimestamp":1779881663,"startTime":"0","endTime":"0","summary":"TG Therapeutics Inc. 宣布，其临床研究的次要终点数据与公司过往的研究结果保持一致。在整个试验过程中，研究人员未观察到任何新的安全性信号，这表明该疗法在当前试验人群中的安全性与先前认知相符。这些发现进一步支持了该疗法的整体安全性特征，为后续的研发和评估提供了重要的数据支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4139","TGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155376428","title":"TG Therapeutics 三期增强试验证实单次600毫克Briumvi输注生物等效性","url":"https://stock-news.laohu8.com/highlight/detail?id=1155376428","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155376428?lang=zh_cn&edition=full","pubTime":"2026-05-27 19:34","pubTimestamp":1779881660,"startTime":"0","endTime":"0","summary":"TG Therapeutics公司公布的三期ENHANCE试验结果显示，在治疗首日单次输注600毫克Briumvi，其生物等效性得到验证。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TGTX","BK4139","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138241879","title":"TG Therapeutics皮下注射Briumvi三期试验顶线数据预计2026年底或2027年初公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1138241879","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138241879?lang=zh_cn&edition=full","pubTime":"2026-04-15 19:34","pubTimestamp":1776252885,"startTime":"0","endTime":"0","summary":"TG Therapeutics公司宣布，其皮下注射制剂Briumvi的三期临床试验顶线数据预计将于2026年底或2027年第一季度揭晓。这项关键研究旨在评估该药物在多重硬化症治疗中的安全性和有效性。\n此次数据公布将成为验证Briumvi皮下给药方案临床价值的重要里程碑。若结果积极，将为患者提供更便捷的治疗选择，并可能进一步拓展该药物的市场潜力。\n公司表示将严格遵循临床试验方案，确保数据收集的完整性和准确性。医学界正密切关注这项研究的进展，因其结果可能对多发性硬化症治疗格局产生深远影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TGTX","BK4139","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173950788","title":"TG Therapeutics宣布完成皮下注射Briumvi三期临床试验患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1173950788","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173950788?lang=zh_cn&edition=full","pubTime":"2026-04-15 19:31","pubTimestamp":1776252678,"startTime":"0","endTime":"0","summary":"TG Therapeutics近日宣布，其针对皮下注射剂型Briumvi开展的三期临床试验已完成患者招募工作。这项重要进展标志着该药物在治疗多发性硬化症领域的研发迈入新阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TGTX","BK4139","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518744086","title":"Tg Therapeutics, Inc.2024财年实现净利润23.38百万美元，同比增加84.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518744086","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518744086?lang=zh_cn&edition=full","pubTime":"2025-03-09 00:01","pubTimestamp":1741449668,"startTime":"0","endTime":"0","summary":"3月9日，Tg Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为23.38百万美元，同比增加84.53%；其中营业收入为3.29亿美元，同比增加40.60%，每股基本收益为0.16美元。机构评级：截至2025年3月9日，当前有6家机构对Tg Therapeutics, Inc.目标价做出预测，其中目标均价为42.83美元，其中最低目标价为10.00美元，最高目标价为55.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000230a266b3d5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000230a266b3d5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","TGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517162677","title":"Tg Therapeutics, Inc.盘中异动 股价大涨5.04%报36.88美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517162677","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517162677?lang=zh_cn&edition=full","pubTime":"2025-03-07 00:04","pubTimestamp":1741277052,"startTime":"0","endTime":"0","summary":"北京时间2025年03月07日00时04分，Tg Therapeutics, Inc.股票出现波动，股价快速拉升5.04%。截至发稿，该股报36.88美元/股，成交量108.177万股，换手率0.69%，振幅6.61%。Tg Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.38%。Tg Therapeutics, Inc.公司简介：TG Therapeutics Inc 是一家完全整合的，商业阶段生物制药公司，专注于 B 细胞疾病新型疗法的获得、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307000412989ec607&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307000412989ec607&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4585","LENZ","BK4588","TGTX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tgtherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.017},{"period":"1month","weight":0.0419},{"period":"3month","weight":0.0228},{"period":"6month","weight":0.6733},{"period":"1year","weight":0.5828},{"period":"ytd","weight":0.8849}],"compareEarnings":[{"period":"1week","weight":-0.0102},{"period":"1month","weight":-0.0049},{"period":"3month","weight":0.0252},{"period":"6month","weight":0.1684},{"period":"1year","weight":0.1568},{"period":"ytd","weight":0.1227}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"TG Therapeutics, Inc.于1993年在特拉华州注册成立。该公司是一家完全整合的、商业化阶段的生物制药公司，专注于B细胞介导疾病新疗法的收购、开发和商业化。其产品BRIUMVI（ublituximab-xiiy）已获得美国、欧盟和英国的监管批准，用于治疗复发性多发性硬化症成人患者。","yearOnYearQuotes":[{"month":1,"riseRate":0.461538,"avgChangeRate":0.050204},{"month":2,"riseRate":0.692308,"avgChangeRate":0.07145},{"month":3,"riseRate":0.692308,"avgChangeRate":0.11238},{"month":4,"riseRate":0.461538,"avgChangeRate":0.020303},{"month":5,"riseRate":0.538462,"avgChangeRate":0.00629},{"month":6,"riseRate":0.571429,"avgChangeRate":0.083309},{"month":7,"riseRate":0.357143,"avgChangeRate":-0.005498},{"month":8,"riseRate":0.571429,"avgChangeRate":-0.025338},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.02767},{"month":10,"riseRate":0.307692,"avgChangeRate":-0.061104},{"month":11,"riseRate":0.846154,"avgChangeRate":0.172847},{"month":12,"riseRate":0.461538,"avgChangeRate":0.09546}],"exchange":"NASDAQ","name":"TG Therapeutics Inc.","nameEN":"TG Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"TG Therapeutics Inc.(TGTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供TG Therapeutics Inc.(TGTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"TG Therapeutics Inc.,TGTX,TG Therapeutics Inc.股票,TG Therapeutics Inc.股票老虎,TG Therapeutics Inc.股票老虎国际,TG Therapeutics Inc.行情,TG Therapeutics Inc.股票行情,TG Therapeutics Inc.股价,TG Therapeutics Inc.股市,TG Therapeutics Inc.股票价格,TG Therapeutics Inc.股票交易,TG Therapeutics Inc.股票购买,TG Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"TG Therapeutics Inc.(TGTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供TG Therapeutics Inc.(TGTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}